Lilly Alzheimer’s Drug Trial Results Give Valuable Insight for Future Research

 

CONTACT: KYLE MOLER
202-478-6173, KMOLER@MRSS.COM

USAgainstAlzheimer's Calls on Political, Business, and Civic Leaders to Strengthen Support and Investment in Alzheimer's Research

WASHINGTON – – Today, Eli Lilly and Company announced the full results of its experimental drug treatment for Alzheimer’s, solanezumab. The initial results, which were announced in late August, found that in two clinical trials the drug failed to slow mental and physical decline in patients who had mild-to-moderate forms of the disease. A secondary analysis of pooled data in patients with mild forms of the disease showed a 34 percent reduction in cognitive decline of patients. Solanezumab is one of several drugs at the forefront of the research fight against Alzheimer’s, a disease that afflicts 5.4 million Americans and is expected to cost the U.S. $200 billion in 2012 alone. Eli Lilly plans to determine next steps for the drug after talks with regulators.

George Vradenburg, Chairman of USAgainstAlzheimer’s, member of the Advisory Council on Alzheimer’s Research, Care, and Services, and an outspoken proponent of adopting an accelerated timeline of stopping Alzheimer’s within the decade, released the following statement in response to the trial results:

"The solanezumab trial broke new ground on the relationship between biomarkers and clinical impact. While a reminder of the great challenge we face, this data sharing is informative to the Alzheimer’s community and is a cause for hope of stopping the disease within the decade because it lays out a clear pathway for the further work that needs to be done to deliver an effective treatment for Alzheimer's.

"Tens of millions of those at risk for Alzheimer's or with mild symptoms are desperate for some disease-modifying treatment. Even if the effect is simply to slow progression, it could lead to many additional years with a better quality of life, and strengthen the likelihood that in time, a second generation treatment will emerge with even greater effect.

"We will only be able to accomplish an historic breakthrough if our nation's political, business and civic leaders commit to support risk-taking companies like Lilly with a focused investment in research, drug system reforms and innovation-oriented reimbursement policies. Without this kind of aggressive strategy and a national commitment that eschews the current ‘business as usual’ approach to Alzheimer’s, we stand to lose millions more lives - and trillions of dollars - to this disease."

For more information about USAgainstAlzheimer’s, or to speak to George Vradenburg, please contact Kyle Moler at kmoler@mrss.comor 202-478-6173.

###

USAgainstAlzheimer’s is a national advocacy campaign and advocacy network committed to stopping Alzheimer’s by 2020. An independent non-profit organization working in partnership with the Alzheimer’s community, USAgainstAlzheimer’s works to advance policies and elect candidates dedicated to stopping the disease by supporting research for a cure. For more information about USAgainstAlzheimer’s, http://www.usagainstalzheimers.org.

Network: 
^ Back to Top